NeoGenomics is a leading oncology diagnostic laboratory services provider offering a comprehensive portfolio of cancer-focused testing modalities, including cytogenetics, flow cytometry, immunohistochemistry, molecular and next-generation sequencing, and molecular residual disease testing across multiple accredited facilities in the United States and United Kingdom. The company serves community pathology practices, hospitals, academic centers, and pharmaceutical firms as a non-competitive partner, providing both technical laboratory testing and professional physician interpretation services that allow clients to expand testing capabilities without major capital investment. Revenue is generated primarily through clinical cancer testing billed directly to clients, supplemented by commercial insurance, government reimbursement, and additional services including pharmaceutical trial support, validation services, and oncology data solutions licensing.